Humanized anti-CCR2 Antibody for the Therapy of MS and RA

Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA).The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.

Further information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-151

Contact
Dr. Jens-Peter Horst

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.